Sort
51,593 grants matching “hepatitis”
Tuberous Sclerosis: Mutations and Murine Models
$398,672David J. Kwiatkowski · Brigham And Women'S Hospital · R37 · FY2012 · NS
High-Tc susceptometer to monitor transfusional iron overload (NSR device)
$398,665Gary M Brittenham · Columbia University Health Sciences · R01 · FY2010 · FD
PGC-1 and the Control of Hepatic Gluconeogenesis
$398,618Dana-Farber Cancer Institute · R01 · FY2005 · DK
Computational discovery of effective hepatitis C intervention strategies
$398,579Harel Dahari · Loyola University Chicago · R01 · FY2021 · GM
Functional Hierarchy of Remnant Lipoprotein Receptors
$398,569Sergio Fazio · Vanderbilt University · R01 · FY2007 · HL
Hepatitis C virus escape mechanisms from innate immunity
$398,529Ranjit Ray · Washington University · U54 · FY2010 · AI
(PQ5) Relevance of VDAC2 heterogeneity for hepatic tumor growth and targeting
$398,508Gyorgy Hajnoczky · Thomas Jefferson University · R01 · FY2021 · CA
MOUSE MODELS OF INSULIN RESISTANCE
$398,483Domenico Accili · Columbia University Health Sciences · R37 · FY2012 · DK
The role of neutral ceramidase in intestinal fucosylation and liver steatosis and inflammation
$398,430Zhong-Bin Deng · University Of Louisville · R01 · FY2025 · DK
Optimization of ERRg-specific ligands as in vivo Chemical Probes
$398,400Theodore M Kamenecka · Scripps Florida · R01 · FY2017 · HD
Optimization of ERRg-specific ligands as in vivo Chemical Probes
$398,400Theodore M Kamenecka · Scripps Florida · R01 · FY2018 · HD
Optimization of ERRg-specific ligands as in vivo Chemical Probes
$398,400Theodore M Kamenecka · Scripps Florida · R01 · FY2016 · HD
Study of Hepatic Arterial Infusion of Melphalan for Malignancy in the liver
$398,395Marybeth Hughes · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Improving the Therapeutic Ratio of Proton Radiation Therapy
$398,368Thomas F Delaney · Massachusetts General Hospital · P01 · FY2012 · CA
Fibrinolysis Evaluation in A-TREAT (âFEATâ Study)
$398,365Nigel S Key · Univ Of North Carolina Chapel Hill · R01 · FY2019 · HL
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
$398,334Serena Patricia Koenig · Brigham And Women'S Hospital · U01 · FY2025 · AI
Histidine Phosphorylation in Mammals: Regulation, Protein Targets, and Biology
$398,325Edward Y Skolnik · New York University School Of Medicine · R01 · FY2022 · GM
Histidine Phosphorylation in Mammals: Regulation, Protein Targets, and Biology
$398,325Edward Y Skolnik · New York University School Of Medicine · R01 · FY2020 · GM
Histidine Phosphorylation in Mammals: Regulation, Protein Targets, and Biology
$398,325Edward Y Skolnik · New York University School Of Medicine · R01 · FY2019 · GM
Modulation of HCV Gene Expression
$398,325Mount Sinai School Of Medicine Of Nyu · R01 · FY2005 · DK
Histidine Phosphorylation in Mammals: Regulation, Protein Targets, and Biology
$398,325Edward Y Skolnik · New York University School Of Medicine · R01 · FY2021 · GM
CYP2B6 Genetic Variations and Drug Interactions
$398,305Zeruesenay Desta · Indiana University Indianapolis · R01 · FY2014 · GM
CYP2B6 Genetic Variations and Drug Interactions
$398,305Zeruesenay Desta · Indiana University Indianapolis · R01 · FY2015 · GM
Ferristatin: A New Small Molecule Inhibitor of Iron Transport
$398,248Marianne Wessling-Resnick · Harvard School Of Public Health · RC1 · FY2010 · DK
Avoiding toxicity associated with MTP ablation
$398,230M Mahmood Hussain · Suny Downstate Medical Center · R01 · FY2011 · HL